Stryker to Invest $400 Million in CMR Surgical, Gets Option to Buy Company
By Connor Hart
Stryker has agreed to invest about $400 million in CMR Surgical, securing an exclusive option to acquire the British surgical-robotics company as it expands into the soft-tissue robotics market.
The medical-technology company said Monday that the agreement also includes an exclusive U.S. commercial agency arrangement, under which Stryker will serve as the sole U.S. sales agent for CMR Surgical's Versius robotic surgery portfolio.
CMR Surgical's Versius platform is designed to support a range of soft-tissue procedures, the companies said. CMR Surgical will continue to oversee development of its Versius portfolio outside of the U.S.
The deal comes as demand for robotic-assisted surgery continues to grow, Stryker said. The company--which already has a presence in orthopedic robotic surgery through its Mako platform--said the agreement builds on its existing capabilities in endoscopy, visualization and other surgical technologies.
"Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker's strengths," said Andy Pierce, group president of Stryker's MedSurg and Neurotechnology business.
Stryker's exclusive option would allow it to acquire 100% of CMR Surgical's outstanding equity in the future, subject to the agreement's terms. The companies didn't disclose the size of the stake Stryker will acquire, or the financial terms of a potential full takeover.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
October 12, 2026 08:58 ET (12:58 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
Christine Benz: Why I Hired a Financial Planner
United States